Drug Profile
TCD 717
Alternative Names: TCD-717Latest Information Update: 23 Mar 2016
Price :
$50
*
At a glance
- Originator TCD Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action CHKA protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 23 Mar 2016 No recent reports on development identified - Phase-I for Solid tumours (Late-stage disease) in USA (IV)
- 28 Feb 2014 TCD Pharma completes a phase I trial in Solid tumours (Late-stage disease) in USA (NCT01215864)
- 31 Jan 2011 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (IV)